Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > As predicted. shorting away

<< Previous

Bullboard Posts

Next >>

Comment by Buckhenryon May 15, 2024 2:17pm

58 Views

Post# 36041639

RE:RE:As predicted. shorting away

Pumpers here have been playing the blame it on someone else like the shorters. Etc. Game Forever. They are and have been in denial for years. Go look in the mirror and point your finger and you will find the person to blame.

<< Previous

Bullboard Posts

Next >>

Yukon agency detects cyanide near Victoria Gold's Eagle mine